For the quarter ending 2025-09-30, BCAX had -$264,933K decrease in cash & cash equivalents over the period. -$29,290K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -36,330 | -64,234 |
| Stock-based compensation | 3,614 | 6,943 |
| Depreciation | 24 | 38 |
| Non-cash lease expense | 249 | 349 |
| Net amortization of premiums and discounts on investments | -32 | - |
| Prepaid expenses and other assets | 301 | -4,743 |
| Accounts payable and accrued expenses-Nonrelated Party | 3,949 | -2,715 |
| Accounts payable and accrued expenses-Related Party | -168 | 1,499 |
| Operating lease liabilities | -317 | -323 |
| Net cash used in operating activities | -29,248 | -53,700 |
| Purchases of investments | 236,079 | - |
| Purchase of property and equipment | 42 | 0 |
| Proceeds from sale of property and equipment | 0 | 0 |
| Net cash (used in)/provided by investing activities | -236,121 | 0 |
| Proceeds from issuance on common stock, net of issuance costs | 0 | - |
| Proceeds from exercise of options | 436 | 595 |
| Payment for deferred offering costs | - | 0 |
| Net cash provided by financing activities | 436 | 595 |
| Net (decrease)/increase in cash and cash equivalents | -264,933 | -53,105 |
| Cash and cash equivalents at beginning of period | 489,711 | - |
| Cash and cash equivalents at end of period | 171,673 | - |
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)